Review





Similar Products

hrg  (Sino Biological)
93
Sino Biological hrg
A9B5-Bs-5 and A9B5-Bs-7 inhibit the growth of trastuzumab-resistant HER2-positive cancer cells. (A, B) Growth inhibition in NCI-N87 (A) and BT474 cells (B) treated with bpAbs in the absence of ligands, measured by CCK-8 assay. (C, D) Growth inhibition in NCI-N87 (C) and BT474 cells (D) treated with bpAbs in the presence <t>of</t> <t>EGF</t> or <t>HRG,</t> measured by CCK-8 assay. Serum-starved cells were incubated with anti-HER2 diluted antibodies in the presence of 1 nM HRG or 5 nM EGF. Horizontal dotted line (black) represents viability of non-treated cells referenced to 100%. Data represent mean ± SD (n = 3). (E) Heat map of EC 50 values (nM) derived from CCK-8 assays showing dose-dependent inhibition by bpAbs. Source data are available in the Source Data file.
Hrg, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nrg1+beta+1+protein/pmc12634555-51-11-12?v=Sino+Biological
Average 93 stars, based on 1 article reviews
hrg - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
nrg1 b1 hrg b1  (R&D Systems)
95
R&D Systems nrg1 b1 hrg b1
A9B5-Bs-5 and A9B5-Bs-7 inhibit the growth of trastuzumab-resistant HER2-positive cancer cells. (A, B) Growth inhibition in NCI-N87 (A) and BT474 cells (B) treated with bpAbs in the absence of ligands, measured by CCK-8 assay. (C, D) Growth inhibition in NCI-N87 (C) and BT474 cells (D) treated with bpAbs in the presence <t>of</t> <t>EGF</t> or <t>HRG,</t> measured by CCK-8 assay. Serum-starved cells were incubated with anti-HER2 diluted antibodies in the presence of 1 nM HRG or 5 nM EGF. Horizontal dotted line (black) represents viability of non-treated cells referenced to 100%. Data represent mean ± SD (n = 3). (E) Heat map of EC 50 values (nM) derived from CCK-8 assays showing dose-dependent inhibition by bpAbs. Source data are available in the Source Data file.
Nrg1 B1 Hrg B1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nrg1+beta+1+protein/10__1158_slash_0008___5472__can___25___4018-282-40-42?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
nrg1 b1 hrg b1 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
neuregulin  (R&D Systems)
95
R&D Systems neuregulin
A9B5-Bs-5 and A9B5-Bs-7 inhibit the growth of trastuzumab-resistant HER2-positive cancer cells. (A, B) Growth inhibition in NCI-N87 (A) and BT474 cells (B) treated with bpAbs in the absence of ligands, measured by CCK-8 assay. (C, D) Growth inhibition in NCI-N87 (C) and BT474 cells (D) treated with bpAbs in the presence <t>of</t> <t>EGF</t> or <t>HRG,</t> measured by CCK-8 assay. Serum-starved cells were incubated with anti-HER2 diluted antibodies in the presence of 1 nM HRG or 5 nM EGF. Horizontal dotted line (black) represents viability of non-treated cells referenced to 100%. Data represent mean ± SD (n = 3). (E) Heat map of EC 50 values (nM) derived from CCK-8 assays showing dose-dependent inhibition by bpAbs. Source data are available in the Source Data file.
Neuregulin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nrg1+beta+1+protein/bio_rxiv__64898__2026__03__17__709302-71-13-15?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
neuregulin - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
neuregulin 1β nrg 1  (R&D Systems)
95
R&D Systems neuregulin 1β nrg 1
A9B5-Bs-5 and A9B5-Bs-7 inhibit the growth of trastuzumab-resistant HER2-positive cancer cells. (A, B) Growth inhibition in NCI-N87 (A) and BT474 cells (B) treated with bpAbs in the absence of ligands, measured by CCK-8 assay. (C, D) Growth inhibition in NCI-N87 (C) and BT474 cells (D) treated with bpAbs in the presence <t>of</t> <t>EGF</t> or <t>HRG,</t> measured by CCK-8 assay. Serum-starved cells were incubated with anti-HER2 diluted antibodies in the presence of 1 nM HRG or 5 nM EGF. Horizontal dotted line (black) represents viability of non-treated cells referenced to 100%. Data represent mean ± SD (n = 3). (E) Heat map of EC 50 values (nM) derived from CCK-8 assays showing dose-dependent inhibition by bpAbs. Source data are available in the Source Data file.
Neuregulin 1β Nrg 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nrg1+beta+1+protein/pm41437739-32-28-32?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
neuregulin 1β nrg 1 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
recombinant human nrg1 β1 hrg1 β1 egf domain  (R&D Systems)
95
R&D Systems recombinant human nrg1 β1 hrg1 β1 egf domain
A9B5-Bs-5 and A9B5-Bs-7 inhibit the growth of trastuzumab-resistant HER2-positive cancer cells. (A, B) Growth inhibition in NCI-N87 (A) and BT474 cells (B) treated with bpAbs in the absence of ligands, measured by CCK-8 assay. (C, D) Growth inhibition in NCI-N87 (C) and BT474 cells (D) treated with bpAbs in the presence <t>of</t> <t>EGF</t> or <t>HRG,</t> measured by CCK-8 assay. Serum-starved cells were incubated with anti-HER2 diluted antibodies in the presence of 1 nM HRG or 5 nM EGF. Horizontal dotted line (black) represents viability of non-treated cells referenced to 100%. Data represent mean ± SD (n = 3). (E) Heat map of EC 50 values (nM) derived from CCK-8 assays showing dose-dependent inhibition by bpAbs. Source data are available in the Source Data file.
Recombinant Human Nrg1 β1 Hrg1 β1 Egf Domain, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nrg1+beta+1+protein/us12486332-261-20-24?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
recombinant human nrg1 β1 hrg1 β1 egf domain - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
ligand nrg1 β1  (R&D Systems)
93
R&D Systems ligand nrg1 β1
A9B5-Bs-5 and A9B5-Bs-7 inhibit the growth of trastuzumab-resistant HER2-positive cancer cells. (A, B) Growth inhibition in NCI-N87 (A) and BT474 cells (B) treated with bpAbs in the absence of ligands, measured by CCK-8 assay. (C, D) Growth inhibition in NCI-N87 (C) and BT474 cells (D) treated with bpAbs in the presence <t>of</t> <t>EGF</t> or <t>HRG,</t> measured by CCK-8 assay. Serum-starved cells were incubated with anti-HER2 diluted antibodies in the presence of 1 nM HRG or 5 nM EGF. Horizontal dotted line (black) represents viability of non-treated cells referenced to 100%. Data represent mean ± SD (n = 3). (E) Heat map of EC 50 values (nM) derived from CCK-8 assays showing dose-dependent inhibition by bpAbs. Source data are available in the Source Data file.
Ligand Nrg1 β1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nrg1+beta+1+protein/us12486332-478-0-2?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
ligand nrg1 β1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
nrg1  (R&D Systems)
93
R&D Systems nrg1
A9B5-Bs-5 and A9B5-Bs-7 inhibit the growth of trastuzumab-resistant HER2-positive cancer cells. (A, B) Growth inhibition in NCI-N87 (A) and BT474 cells (B) treated with bpAbs in the absence of ligands, measured by CCK-8 assay. (C, D) Growth inhibition in NCI-N87 (C) and BT474 cells (D) treated with bpAbs in the presence <t>of</t> <t>EGF</t> or <t>HRG,</t> measured by CCK-8 assay. Serum-starved cells were incubated with anti-HER2 diluted antibodies in the presence of 1 nM HRG or 5 nM EGF. Horizontal dotted line (black) represents viability of non-treated cells referenced to 100%. Data represent mean ± SD (n = 3). (E) Heat map of EC 50 values (nM) derived from CCK-8 assays showing dose-dependent inhibition by bpAbs. Source data are available in the Source Data file.
Nrg1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nrg1+beta+1+protein/pm41117277-60-34-40?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
nrg1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


A9B5-Bs-5 and A9B5-Bs-7 inhibit the growth of trastuzumab-resistant HER2-positive cancer cells. (A, B) Growth inhibition in NCI-N87 (A) and BT474 cells (B) treated with bpAbs in the absence of ligands, measured by CCK-8 assay. (C, D) Growth inhibition in NCI-N87 (C) and BT474 cells (D) treated with bpAbs in the presence of EGF or HRG, measured by CCK-8 assay. Serum-starved cells were incubated with anti-HER2 diluted antibodies in the presence of 1 nM HRG or 5 nM EGF. Horizontal dotted line (black) represents viability of non-treated cells referenced to 100%. Data represent mean ± SD (n = 3). (E) Heat map of EC 50 values (nM) derived from CCK-8 assays showing dose-dependent inhibition by bpAbs. Source data are available in the Source Data file.

Journal: Frontiers in Immunology

Article Title: Engineering HER2-targeted biparatopic antibodies to promote receptor internalization and restore antitumor efficacy

doi: 10.3389/fimmu.2025.1711433

Figure Lengend Snippet: A9B5-Bs-5 and A9B5-Bs-7 inhibit the growth of trastuzumab-resistant HER2-positive cancer cells. (A, B) Growth inhibition in NCI-N87 (A) and BT474 cells (B) treated with bpAbs in the absence of ligands, measured by CCK-8 assay. (C, D) Growth inhibition in NCI-N87 (C) and BT474 cells (D) treated with bpAbs in the presence of EGF or HRG, measured by CCK-8 assay. Serum-starved cells were incubated with anti-HER2 diluted antibodies in the presence of 1 nM HRG or 5 nM EGF. Horizontal dotted line (black) represents viability of non-treated cells referenced to 100%. Data represent mean ± SD (n = 3). (E) Heat map of EC 50 values (nM) derived from CCK-8 assays showing dose-dependent inhibition by bpAbs. Source data are available in the Source Data file.

Article Snippet: For ligand-dependent assays, tumor cells were stimulated with either 1 nM HRG (SinoBiological, 11609-HNCH) or 5 nM EGF (SinoBiological, GMP-10605-HNAE).

Techniques: Inhibition, CCK-8 Assay, Incubation, Derivative Assay